Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN), Beam Therapeutics (BEAM) and Thermo Fisher (TMO) with bullish sentiments.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioMarin Pharmaceutical (BMRN)
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $120.00. The company’s shares closed last Wednesday at $50.20.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of
Currently, the analyst consensus on BioMarin Pharmaceutical is a Moderate Buy with an average price target of $86.72, which is a 74.1% upside from current levels. In a report issued on May 15, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $75.00 price target.
See today’s best-performing stocks on TipRanks >>
Beam Therapeutics (BEAM)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Beam Therapeutics, with a price target of $80.00. The company’s shares closed last Wednesday at $27.11.
According to TipRanks.com, Trucchio is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Beam Therapeutics with a $49.91 average price target, implying an 87.3% upside from current levels. In a report issued on May 7, JonesTrading also maintained a Buy rating on the stock with a price target.
Thermo Fisher (TMO)
Wells Fargo analyst Brandon Couillard maintained a Buy rating on Thermo Fisher today and set a price target of $615.00. The company’s shares closed last Wednesday at $451.79.
According to TipRanks.com, Couillard is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Thermo Fisher with a $610.64 average price target, implying a 36.0% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
Read More on BMRN:
